¼¼°èÀÇ ½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀå
Cardiovascular Clinical Trials
»óǰÄÚµå : 1774691
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 393 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀåÀº 2030³â±îÁö 74¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 56¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÉÇ÷°ü ÀÓ»ó½ÃÇè ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 74¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¦IV»ó ÀÓ»ó½ÃÇèÀº CAGR 5.5%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 34¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦III»ó ÀÓ»ó½ÃÇè ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 15¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀåÀº 2024³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 16¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.7%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.9%¿Í 3.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½ÉÇ÷°ü ÀÓ»ó½ÃÇè ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯

½ÉÇ÷°ü ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä´Â ½ÉÀåÁúȯÀÇ À¯º´·ü Áõ°¡, Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¤¹ÐÀÇ·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÉºÎÀü, °ü»óµ¿¸ÆÁúȯ, °íÇ÷¾Ð, ºÎÁ¤¸Æ µî ½ÉÇ÷°ü ÁúȯÀº ¿©ÀüÈ÷ Àü ¼¼°è »ç¸Á¿øÀÎ 1À§ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´¿¡ ´ëÇÑ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â ½Å¾à, ÀÇ·á±â±â, Ä¡·á ÇÁ·ÎÅäÄÝÀ» °³¹ßÇϱâ À§ÇØ ÀÓ»ó ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.

FDA, EMA ¹× ±âŸ ¼¼°è º¸°Ç ´ç±¹ µî ±ÔÁ¦ ´ç±¹µµ »õ·Î¿î ½ÉÇ÷°ü Ä¡·áÁ¦¸¦ ½ÂÀÎÇϱâ Àü¿¡ È®°íÇÑ ÀÓ»óÀû ±Ù°Å°¡ ÇÊ¿äÇÏ´Ù´Â Á¡À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÀÇ·á¿Í Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÉÇ÷°ü Áúȯ¿¡ ´ëÇÑ À¯ÀüÀÚ Ä¡·á, »ý¹°ÇÐÀû Á¦Á¦, Á¤¹Ð ±â¹Ý Ä¡·á¹ý °³¹ßÀ» À§ÇÑ ÀÓ»ó½ÃÇèÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó ¿¬±¸ ³×Æ®¿öÅ©¿Í µðÁöÅÐ ÀÓ»ó½ÃÇè Ç÷§ÆûÀÇ È®ÀåÀ¸·Î ¿©·¯ Áö¿ª¿¡¼­ ȯÀÚ¸¦ ¸ðÁýÇÏ°í ´ë±Ô¸ð ½ÉÇ÷°ü ÀÓ»ó½ÃÇèÀ» ½±°Ô ¼öÇàÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÇ·áÁø°ú ¿¬±¸ÀÚµéÀÌ ½ÉÇ÷°ü Ä¡·áÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥, Çõ½ÅÀûÀÎ ½ÉÀ庴 Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÓ»ó½ÃÇèÀÇ ¼ö´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ¾î¶»°Ô ½ÉÇ÷°ü ÀÓ»ó½ÃÇèÀ» °³¼±Çϰí Àִ°¡?

ÀΰøÁö´É, µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿, ¸®¾ó¿ùµå Áõ°Å ¼öÁýÀÇ ±â¼ú ¹ßÀüÀº ½ÉÇ÷°ü ÀÓ»ó½ÃÇèÀÇ È¿À²¼º°ú Á¤È®¼ºÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â ȯÀÚ ¸ðÁý ¹× ½ÃÇè ¸ð´ÏÅ͸µ¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» Ȱ¿ëÇÏ´Â °ÍÀ¸·Î, AI ±â¹Ý Ç÷§ÆûÀº ´ë±Ô¸ð µ¥ÀÌÅÍ ¼¼Æ®¸¦ ºÐ¼®ÇÏ¿© ½ÉÇ÷°ü ½ÃÇè¿¡ ÀûÇÕÇÑ Èĺ¸ÀÚ¸¦ ½Äº°Çϰí, ºñ¿ë°ú ±â°£À» ÁÙÀ̸鼭 ȯÀÚ ¼±Åðú À¯Áö¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« Çõ½ÅÀº ÀÓ»ó½ÃÇè¿¡¼­ ¿þ¾î·¯ºí ±â¼ú°ú ¿ø°Ý ¸ð´ÏÅ͸µ ±â±âÀÇ ÅëÇÕÀÔ´Ï´Ù. ½º¸¶Æ®¿öÄ¡, ECG ÆÐÄ¡, ¹ÙÀÌ¿À¼¾¼­´Â ½É¹Ú¼ö, Ç÷¾Ð ¹× ±âŸ ÁÖ¿ä ½ÉÇ÷°ü°è ÁöÇ¥¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ µ¥ÀÌÅÍ ¼öÁýÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ¿¬±¸Àڵ鿡°Ô ¾à¹°ÀÇ È¿°ú¿Í ¾ÈÀü¼º¿¡ ´ëÇÑ ½Ç½Ã°£ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ºÐ»êÇü ÀÓ»ó½ÃÇè°ú °¡»ó ÀÓ»ó½ÃÇèÀÇ È°¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ȯÀÚµéÀº ÀÓ»ó½ÃÇè ±â°üÀ» ¹æ¹®ÇÏÁö ¾Ê°íµµ Áý¿¡¼­µµ ÀÓ»ó½ÃÇè¿¡ Âü¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ°ú µ¥ÀÌÅÍ º¸¾ÈÀ» À§ÇÑ ºí·ÏüÀεµ Åõ¸í¼º°ú ±ÔÁ¦ Áؼö¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ½ÉÇ÷°ü ÀÓ»ó½ÃÇèÀº º¸´Ù ÀûÀÀ·Â ÀÖ°í, È¿À²ÀûÀ̸ç, ȯÀÚ Áß½ÉÀÇ ÀÓ»ó½ÃÇèÀ¸·Î °Åµì³ª°í ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü ÀÓ»ó½ÃÇè »ê¾÷ÀÇ ¼ºÀåÀ» °ßÀÎÇÏ´Â ½ÃÀå µ¿ÇâÀº?

½ÉÇ÷°ü Ä¡·á¿¡¼­ Á¤¹ÐÀÇ·áÀÇ Ã¤Åà Áõ°¡´Â ½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀåÀ» Çü¼ºÇÏ´Â °¡Àå ¿µÇâ·Â ÀÖ´Â Æ®·»µå Áß ÇϳªÀÔ´Ï´Ù. ¿¬±¸ °³¹ßÀº ½ÉÀ庴 ȯÀÚ¸¦ À§ÇÑ º¸´Ù °³ÀÎÈ­µÈ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµ, ¹ÙÀÌ¿À¸¶Ä¿, Ç¥ÀûÄ¡·á¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ȯÀÚ °³°³Àο¡°Ô ¸ÂÃãÈ­µÈ ÁßÀ縦 ÅëÇØ Ä¡·á °á°ú¸¦ °³¼±ÇϰíÀÚ ÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ ÁÖµµÇü ½ÃÇè ¹× µ¿¹Ý Áø´Ü ½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¶Ç ´Ù¸¥ ÁÖ¿ä Æ®·»µå´Â Àӻ󿬱¸¿¡¼­ ¸®¾ó¿ùµå¿¡ºñ´ø½º(RWE)ÀÇ È®´ëÀÔ´Ï´Ù. ±ÔÁ¦ ´ç±¹°ú Á¦¾à»çµéÀº ÀüÀÚÀǹ«±â·Ï, ¿þ¾î·¯ºí ±â±â, ȯÀÚ µî·ÏÀ» ÅëÇØ ¼öÁýµÈ ½ÇÁ¦ µ¥ÀÌÅ͸¦ Ȱ¿ëÇÏ¿© ±âÁ¸ ÀÓ»ó½ÃÇè °á°ú¸¦ º¸¿ÏÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº ÀÓ»ó½ÃÇè °á°úÀÇ ÀϹÝÈ­ °¡´É¼ºÀ» ³ôÀÌ°í »õ·Î¿î ½ÉÇ÷°ü Ä¡·áÁ¦ÀÇ ½ÂÀÎÀ» ¾Õ´ç±æ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç, ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO), Çмú±â°ü °£ÀÇ Çù·ÂÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î ´Ù±â°ü ½ÉÇ÷°ü ÀÓ»ó½ÃÇèÀÌ ´õ¿í Ȱ¹ßÇÏ°Ô ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ¹æ¹ýÀÌ °è¼Ó ÁøÈ­ÇÔ¿¡ µû¶ó ¾÷°è´Â º¸´Ù ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀ̸ç Á¾ÇÕÀûÀÎ ¿¬±¸ ¸ðµ¨·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀåÀÇ ¹Ì·¡¸¦ Á¿ìÇÒ ÁÖ¿ä ¼ºÀå µ¿·ÂÀº ¹«¾ùÀΰ¡?

½ÉÇ÷°ü ÀÓ»ó½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÀ庴 À¯º´·ü Áõ°¡, ÀǾàǰ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Àӻ󿬱¸¿¡¼­ µðÁöÅÐ Çコ ±â¼úÀÇ Ã¤Åà Ȯ´ë µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â ½É¹ÚÃâ·® À¯Áö ½ÉºÎÀü(HFpEF), ÀúÇ×¼º °íÇ÷¾Ð, Á׻󵿸ưæÈ­Áõ°ú °°Àº Ä¡·á ÀúÇ×¼º ÁúȯÀ» ÇØ°áÇϱâ À§ÇÑ »õ·Î¿î ½ÉÇ÷°ü°è Ä¡·áÁ¦¿¡ ´ëÇÑ ±ä±ÞÇÑ ¼ö¿äÀÔ´Ï´Ù. Á¦¾à»çµéÀÌ È¹±âÀûÀÎ Ä¡·á¹ýÀ» ã´Â °¡¿îµ¥ ½ÉÇ÷°ü ÀÓ»ó½ÃÇèÀÇ ¾ç°ú º¹À⼺Àº °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀ» Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ÃËÁø¿äÀÎÀº ½ÉÇ÷°ü ¿¬±¸¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ÀÚ±Ý Áö¿øÀÇ ¿ªÇÒÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Á¤ºÎ ±â°ü, ºñ¿µ¸® ´Üü, ÇコÄɾî Àç´ÜÀº ƯÈ÷ »ç¸Á·üÀÌ ³ôÀº Áúȯ¿¡ ´ëÇÑ ½ÉÇ÷°ü ¿¬±¸¿¡ ´õ ¸¹Àº ÀÚ¿øÀ» ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ¸ð´ÏÅ͸µ°ú °¡»ó »ó´ãÀ» ÀÌ¿ëÇÑ ºÐ»êÇü ÀÓ»ó½ÃÇèÀÇ È®´ë·Î ´Ù¾çÇÑ È¯ÀÚ Áý´ÜÀÌ ½±°Ô Âü¿©ÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÓ»ó½ÃÇèÀÇ Æ÷°ý¼º°ú ´Ù¾ç¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ ½ÉÇ÷°ü°è Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÓ»ó½ÃÇèÀº ½ÉÀå Áúȯ °ü¸®¸¦ ¹ßÀü½Ã۰í Àü ¼¼°è ½ÉÇ÷°ü°è °Ç°­ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» °è¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

´Ü°è( Á¦IV»ó ÀÓ»ó½ÃÇè, Á¦III»ó ÀÓ»ó½ÃÇè, Á¦II»ó ÀÓ»ó½ÃÇè, Á¦I»ó ÀÓ»ó½ÃÇè);½ÃÇè µðÀÚÀÎ(°³ÀÔ ½ÃÇè, °üÂû ½ÃÇè, È®´ë ¾×¼¼½º ½ÃÇè);ÀûÀÀÁõ(°ü»óµ¿¸Æ Áúȯ ÀûÀÀÁõ, ÇãÇ÷¼º ½ÉÁúȯ ÀûÀÀÁõ, ³úÁ¹Áß ÀûÀÀÁõ, ½ÉºÎÀü ÀûÀÀÁõ, ½ÉºÎÁ¤¸Æ ÀûÀÀÁõ, ±Þ¼º°üÁõÈıº ÀûÀÀÁõ, Æóµ¿¸Æ¼º Æó°íÇ÷¾ÐÁõ ÀûÀÀÁõ, ±âŸ ÀûÀÀÁõ).

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cardiovascular Clinical Trials Market to Reach US$7.4 Billion by 2030

The global market for Cardiovascular Clinical Trials estimated at US$5.6 Billion in the year 2024, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Phase IV Clinical Trial, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Phase III Clinical Trial segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.7% CAGR

The Cardiovascular Clinical Trials market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Cardiovascular Clinical Trials Market - Key Trends & Drivers Summarized

Why Is the Demand for Cardiovascular Clinical Trials Increasing

The demand for cardiovascular clinical trials is increasing due to the rising prevalence of heart diseases, the growing need for innovative treatments, and advancements in precision medicine. Cardiovascular diseases, including heart failure, coronary artery disease, hypertension, and arrhythmias, remain the leading cause of mortality worldwide. As the burden of these conditions grows, pharmaceutical and biotechnology companies are investing heavily in clinical research to develop new drugs, medical devices, and treatment protocols that improve patient outcomes.

Regulatory agencies such as the FDA, EMA, and other global health authorities are also emphasizing the need for robust clinical evidence before approving new cardiovascular therapies. The growing focus on personalized medicine and targeted therapies has led to an increasing number of trials aimed at developing gene therapies, biologics, and precision-based treatments for cardiovascular diseases. Additionally, the expansion of clinical research networks and digital trial platforms has made it easier to recruit patients and conduct large-scale cardiovascular studies across multiple regions. As healthcare providers and researchers strive to address the unmet needs in cardiovascular care, the number of clinical trials focused on innovative heart disease treatments continues to rise.

How Are Technological Advancements Improving Cardiovascular Clinical Trials

Technological advancements in artificial intelligence, digital biomarkers, and real-world evidence collection are transforming the efficiency and accuracy of cardiovascular clinical trials. One of the most significant advancements is the use of artificial intelligence and machine learning in patient recruitment and trial monitoring. AI-powered platforms can analyze large datasets to identify suitable candidates for cardiovascular trials, improving patient selection and retention while reducing costs and timeframes.

Another major breakthrough is the integration of wearable technology and remote monitoring devices in clinical trials. Smartwatches, ECG patches, and biosensors allow for continuous data collection on heart rate variability, blood pressure, and other key cardiovascular metrics, providing researchers with real-time insights into drug efficacy and safety. Additionally, the use of decentralized and virtual trials is expanding, enabling patients to participate in studies from home rather than traveling to clinical sites. Cloud-based trial management systems and blockchain for data security are also improving transparency and regulatory compliance. As technology continues to advance, cardiovascular clinical trials are becoming more adaptive, efficient, and patient-centric.

Which Market Trends Are Driving Growth in the Cardiovascular Clinical Trials Industry

The increasing adoption of precision medicine in cardiovascular care is one of the most influential trends shaping the cardiovascular clinical trials market. Researchers are focusing on genetic profiling, biomarkers, and targeted therapies to develop more personalized treatments for heart disease patients. This trend is driving the demand for biomarker-driven trials and companion diagnostic studies that aim to improve treatment outcomes by tailoring interventions to individual patients.

Another key trend influencing market growth is the expansion of real-world evidence (RWE) in clinical research. Regulatory agencies and pharmaceutical companies are leveraging real-world data collected from electronic health records, wearable devices, and patient registries to supplement traditional clinical trial findings. This approach enhances the generalizability of trial results and accelerates the approval of new cardiovascular therapies. Additionally, collaborations between pharmaceutical companies, contract research organizations (CROs), and academic institutions are increasing, leading to more global, multi-center cardiovascular trials. As clinical trial methodologies continue to evolve, the industry is shifting toward faster, more cost-effective, and inclusive research models.

What Are the Key Growth Drivers Shaping the Future of the Cardiovascular Clinical Trials Market

The growth in the cardiovascular clinical trials market is driven by several key factors, including the rising incidence of heart disease, increasing investment in drug development, and the growing adoption of digital health technologies in clinical research. One of the primary growth drivers is the urgent need for novel cardiovascular therapies to address treatment-resistant conditions such as heart failure with preserved ejection fraction (HFpEF), resistant hypertension, and atherosclerosis. As pharmaceutical companies seek breakthrough therapies, the volume and complexity of cardiovascular trials continue to increase.

Another crucial driver shaping the market is the increasing role of regulatory support and funding for cardiovascular research. Government agencies, non-profit organizations, and healthcare foundations are allocating more resources toward cardiovascular trials, particularly for conditions with high mortality rates. Additionally, the expansion of decentralized trials, which use remote monitoring and virtual consultations, is making it easier for diverse patient populations to participate, improving trial inclusivity and diversity. As the demand for innovative cardiovascular treatments grows, clinical trials will continue to play a pivotal role in advancing heart disease management and improving global cardiovascular health outcomes.

SCOPE OF STUDY:

The report analyzes the Cardiovascular Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase IV Clinical Trial, Phase III Clinical Trial, Phase II Clinical Trial, Phase I Clinical Trial); Study Design (Interventional Studies, Observational Studies, Expanded Access Studies); Indication (Coronary Artery Disease Indication, Ischemic Heart Disease Indication, Stroke Indication, Heart Failure Indication, Cardiac Arrhythmias Indication, Acute Coronary Syndrome Indication, Pulmonary Arterial Hypertension Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â